Immune Checkpoint Inhibitor Myocarditis and Myotoxicity.

ICI-associated myocarditis is part of a systemic cardiomuscular syndrome with variable severity, affecting up to 50% of cases and requiring tailored management strategies.

• Why it matters: Understanding this complication is crucial because it can be fatal and often presents with overlapping symptoms, making diagnosis and treatment challenging in cancer patients receiving immune checkpoint inhibitors.
• What they did: The study reviews clinical features, stratification criteria, and management approaches for ICI-related myotoxicity, including 50 cases and the use of biomarkers, imaging, and multidisciplinary care.
• The result: Early identification and stratification enable appropriate monitoring and intervention, with emerging therapies like abatacept and ruxolitinib showing promise for severe cases, guiding future treatment protocols.